Thiazolidinediones for the treatment of type 2 diabetes
| Autor: | J.F. Blicklé, J.W.F. Elte |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
medicine.medical_specialty
endocrine system diseases business.industry Insulin medicine.medical_treatment Type 2 Diabetes Mellitus Type 2 diabetes Pharmacology medicine.disease Metformin Endocrinology Insulin resistance Internal medicine Internal Medicine medicine Metabolic syndrome Rosiglitazone business Pioglitazone medicine.drug |
| Zdroj: | European journal of internal medicine. 18(1) |
| ISSN: | 0953-6205 |
| Popis: | Thiazolidinediones (TZD), or glitazones, represent a new generation of antidiabetic drugs that have recently been introduced in Europe. They improve insulin resistance, one of the key anomalies involved in the pathogenesis of type 2 diabetes mellitus, by activating the nuclear peroxoxisome proliferator activated receptor-gamma (PPAR-gamma), leading to crucial metabolic alterations in adipose tissue. Rosiglitazone and pioglitazone have been shown to be active as monotherapy, in combination therapy with metformin or sulfonylureas, and even in triple therapy. They are generally well tolerated but can induce fluid retention. Cardiac failure is a contraindication for the use of TZDs, as is the concomitant administration of insulin. Aside from their effect on glycemic control, TZDs act on several cardiovascular risk factors and may protect pancreatic beta cells from apoptosis. The cardiovascular protective effect of TZDs has recently been demonstrated with the results of the PROactive study, and long-term preservation of beta-cell function is currently under further investigation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect